Success Metrics

Active Trials
3(30%)

Phase Distribution

Ph phase_3
6
60%
Ph phase_2
1
10%
Ph not_applicable
1
10%
Ph phase_1
2
20%

Phase Distribution

2

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
6(60.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

10

all time

Status Distribution
Active(10)

Detailed Status

Not yet recruiting7
Recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 21 (10.0%)
Phase 36 (60.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting770%
recruiting220%
active_not_recruiting110%

Recent Activity

3 active trials
Showing 5 of 10
not_yet_recruitingphase_1

A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

NCT07692048
recruitingphase_3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

NCT06927986
not_yet_recruitingphase_3

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

NCT07672223
not_yet_recruitingphase_3

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

NCT07376382
not_yet_recruitingphase_3

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

NCT07442565
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07692048Phase 1

A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

Not Yet Recruiting
NCT06927986Phase 3

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Recruiting
NCT07672223Phase 3

A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)

Not Yet Recruiting
NCT07376382Phase 3

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Not Yet Recruiting
NCT07442565Phase 3

SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ

Not Yet Recruiting
NCT07417735Phase 3

SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

Not Yet Recruiting
NCT07406542Phase 3

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Not Yet Recruiting
NCT07256509Phase 2

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Not Yet Recruiting
NCT07241936Phase 1

A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors

Recruiting
NCT07104877Not Applicable

A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors

Active Not Recruiting

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10